Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Generics
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Generics
Viatris has announced that the antitrust division of the US Department of Justice (DOJ) has concluded its investigation into Mylan and its former president, Rajiv Malik. 3 July 2024
Generics
An activist investor has renewed its effort to prevent Taro Pharmaceutical from accepting a buyout bid from Sun Pharmaceutical. 24 April 2024
Generics
Generic drugmaker Apotex has reached an agreement to acquire fellow Canada-based Searchlight Pharma. 5 April 2024
Generics
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
Generics
Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. 11 March 2024
Generics
In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical is to hive off its active pharmaceutical ingredient (API) business. 1 February 2024
Generics
Sun Pharmaceutical Industries of India announced its intention to acquire all outstanding shares of US generics drugmaker Taro Pharmaceutical Industries at a price of $43 per share in cash, the companies announced. 19 January 2024
Generics
Taiwan’s Bora Pharmaceuticals is to acquire Upsher-Smith Laboratories, a US generics manufacturer. 17 January 2024
Generics
South Africa's largest drugmaker Aspen Pharmacare has announced an agreement with newly-independent generics drugmaker Sandoz, related to its Chinese business. 7 December 2023
Generics
Portuguese contract development and manufacturing organization (CDMO) Hovione has acquired the start-up ExtremoChem for an undisclosed amount. 20 November 2023
Generics
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year. 8 November 2023
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Generics
Indian drugmaker Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), which focuses on producing active pharmaceutical ingredients (APIs). 22 September 2023
Generics
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
Generics
Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy. 14 April 2023
Generics
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Generics
Private equity firm SK Capital Partners has entered into a deal to acquire Apotex Pharmaceutical Holdings, a Canada-based generic drugmaker with products across all major therapeutic areas for patients around the world. 29 September 2022
Generics
As has largely been expected, South Africa's largest drugmaker, Aspen Pharmacare has confirmed its ongoing interest in buying Australia's Sigma Pharmaceuticals, but at the lower rate of A$0.55 per share, compared with its original, non-binding offer of A$0.60 (The Pharma Letters May 24 and July 6), the latter company revealed in a web site posting. Sigma shares rose as much as 19% to A$0.47 on the announcement. 7 July 2010
Generics
As South African drugmaker Aspen Pharmacare's extended exclusivity period for review and due diligence with respect to its proposed takeover of Australia's Sigma Pharmaceuticals came to an end yesterday, and the latter's share price fell to a six-week low, speculation came to the fore that Aspen would lower its non-binding offer price of A$0.60 a share (around $1.2 billion in total including debt; The Pharma Letter May 24). 6 July 2010
Generics
Israeli generic drugs giant Teva Pharmaceutical Industries Ltd. has exercised its option to invest an additional $11.9 million in diabetes drug developer Andromeda Biotech at a company value of $170 million, report the local news service Globes Online. 15 June 2010
Generics
UK drugs giant GlaxoSmithKline is extending its reach into emerging markets, revealing yesterday that it buying full control of a leading Argentinean drugmaker, Laboratorios Phoenix, for a cash consideration of around $253 million, and gaining a stronger foot hold in Argentina's pharmaceutical market, which is valued at about $3 billion by IMS Health. 11 June 2010
Generics
Chennai, India-based generic drugmaker Orchid Chemicals & Pharmaceuticals says that it had entered into an agreement to acquire Karalex Pharma, a US-based generic marketing and sales services company headquartered in New Jersey, through an all-cash deal for an undisclosed amount. The transaction is expected to close by this month subject to customary closing conditions. 11 June 2010
Generics
Indian drugmaker Lupin is planning a second acquisition in Japan, where it became the seventh largest generics player after buying local firm Kyowa Pharmaceuticals in 2007 for around $100 million, according to a report from Livemint, a part of HT Media 2 June 2010
Generics
Confirming both the drug major's diversification strategy and recent rumors of an acquisition in the Japanese generics market, France's Sanofi-Aventis this morning revealed that it has entered into an agreement with Nichi-Iko Pharmaceuticals to establish a new joint venture, called sanofi-aventis Nichi-Iko KK, in order to develop a generic business in Japan. 28 May 2010
Generics
Amid concerns about its domestic pharmaceutical companies selling out to foreign groups - the latest being Piramal to USA health care giant Abbott Laboratories (The Pharma Letter May 21) - India's Ministry of Health is planning to call a meeting of drug industry executives on the matter, reports PharmaBiz. 28 May 2010
Generics
Shortly after troubled Australian drugmaker Sigma Pharmaceuticals revealed that it had received an unsolicited takeover offer last Friday (The Pharma Letter May 21), South Africa's Aspen PharmaCare announced that it was the mystery bidder. 24 May 2010
Generics
Fooling all the speculators, US health care major Abbott Laboratories has declared its intention to acquire Indian branded generics drugmaker Piramal Healthcare's Solutions business (Domestic Formulations), for an up-front payment of $2.12 billion, plus $400 million annually for the next four years (for a total of $3.72 billion), and will result in Abbott gaining number one position in the Indian pharmaceutical market. 21 May 2010
Generics
Further extending its reach into emerging markets, UK drugs giant GlaxoSmithKline has entered into a strategic alliance with Dong-A Pharmaceuticals, the number one pharmaceutical and over-the-counter medicines company in South Korea. As part of the transaction, GSK will acquire a 9.9% equity shareholding in Dong-A for 73.9 million ($108.5 million). Closing of the transaction is subject to fulfilment of certain conditions as agreed between GSK and Dong-A. 12 May 2010
Generics
Last week, Brazil's Supreme Court of Justice (STJ) ruled that the validity of the patent which guarantees the right of exclusivity of US drugs behemoth Pfizer for the manufacture and marketing of the erectile dysfunction drug Viagra (sildenafil) expires on June 20. 4 May 2010
Generics
In Business Monitor International's updated, second-quarter 2010 Business Environment Ratings (BER) table for the 10 major countries of the Americas, Venezuela is once again ranked the lowest, reaffirming its view that the country remains one of the most challenging pharmaceutical markets in the region. 30 April 2010
Generics
California, USA-based Valeant Pharmaceuticals International says that it has signed a binding agreement to acquire an unnamed, privately-held pharmaceutical company located in Brazil, for 97 million reals ($56 million). 22 April 2010
Generics
Swiss drug major Novartis' generics subsidiary Sandoz has signed a definitive agreement to acquire Oriel Therapeutics, a privately-held US company, gaining exclusive rights to a portfolio of generic drug candidates and related technologies targeting medicines in the inhalable respiratory drug market, notably asthma and chronic obstructive pulmonary disease (COPD). Financial terms of the deal were not disclosed. 19 April 2010
Generics
In two pieces of M&A related news, German generic drugmaker Stada has revealed that it would be open to an attractive takeover offer, though adding to could fend off any unattractive advances. Also, USA-based OSI Pharmaceuticals has agreed to let hostile bidder Japan's Astellas Pharma to review certain confidential information. 31 March 2010
Generics
California, USA-based Valeant Pharmaceuticals International says it has signed a binding agreement to acquire a private, branded generics and over-the-counter (OTC) medicines company located in Brazil for around $28 million. 22 March 2010
Generics
After many months of speculation and behind the scenes activity, Germany's second largest generics drugmaker Ratiopharm (after Hexal, a part of Swiss drug major Novartis' generics unit Sandoz), has been secured by already the world's biggest copy drug company Israel's Teva Pharmaceutical Industries (The Pharma Letters passim). 19 March 2010
Generics
UK drug giant GlaxoSmithKline, like many other pharmaceutical majors, is looking to increase its presence in the fast-growing Indian market. "We are looking for acquisitions in India which are attractive to us. We are a very financially strong company," GSK chief executive Andrew Witty told reporters after inaugurating the company's facility for manufacturing albendazole, an anti-parasitic drug, at the Nashik site in India, yesterday. 9 March 2010
Generics
Elanco, the animal health division of US drug major Eli Lilly has signed an agreement to acquire the European rights to a portfolio of certain Pfizer Animal Health products. The products, including vaccines, parasiticides and feed additives, are used in both the production animal and companion animal markets. Terms of the transaction are not disclosed. 9 March 2010
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze